Tissue distribution of perlecan domains III and V during embryonic and fetal human development

被引:0
作者
Roediger, Matthias [1 ]
Kruegel, Jenny [1 ]
Miosge, Nicolai [1 ]
Gersdorff, Nikolaus [1 ]
机构
[1] Univ Gottingen, Tissue Regenerat Work Grp, Dept Prosthodont, D-37075 Gottingen, Germany
关键词
Perlecan; Basement membrane; Human embryogenesis; Immunohistochemistry; HEPARAN-SULFATE PROTEOGLYCAN; SCHWARTZ-JAMPEL-SYNDROME; BASEMENT-MEMBRANES; CELL-ADHESION; EXPRESSION; LAMININ; BINDS; FIBULIN-2; NIDOGEN; LOCALIZATION;
D O I
暂无
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
A major component of basement membranes (BMs) is perlecan, a five-domain heparan sulphate proteoglycan. During murine embryogenesis, nearly all BMs of mesenchymal origin express perlecan, and it is believed to participate in the supramolecular assembly of BMs. However, the distribution of perlecan in human embryonic and fetal tissues is widely unknown, except for cartilage anlagen of developing extremities and the fetal spine. Clinical syndromes, caused by perlecan-associated mutations or gene-defects, suggest its multifunctional involvement during human development. Here we reveal the immunohistochemistry of perlecan domains III and V during human development from gestational weeks (gw) 6 to 12 in basement membrane zones (BMZs) of the developing brain, nervous system, blood vessels, skin, lung, heart, kidney, liver, intestine and skeletal system. Interestingly, a difference in the distribution of the two perlecan domains was found in the endoneurium of ganglia. Domain III is strongly present from gw 6 onwards, while domain V shows attenuated expression at this stage and has been detected abundantly only from gw 8 onwards, possibly indicating vascularization of the endoneurium during this early stage. We found perlecan to be present particularly at those stages of human development where epithelial-mesenchymal interactions occur.
引用
收藏
页码:859 / 868
页数:10
相关论文
共 53 条
[41]  
2-I
[42]   Embryology of neural tube development [J].
Sadler, TW .
AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS, 2005, 135C (01) :2-8
[43]   EARLY ORGANOGENESIS OF THE KIDNEY [J].
SAXEN, L ;
SARIOLA, H .
PEDIATRIC NEPHROLOGY, 1987, 1 (03) :385-392
[44]   Structural and cell-adhesive properties of three recombinant fragments derived from perlecan domain III [J].
Schulze, B ;
Sasaki, T ;
Costell, M ;
Mann, K ;
Timpl, R .
MATRIX BIOLOGY, 1996, 15 (05) :349-357
[45]   The role of perlecan in arterial injury and angiogenesis [J].
Segev, A ;
Nili, N ;
Strauss, BH .
CARDIOVASCULAR RESEARCH, 2004, 63 (04) :603-610
[46]  
Smith L T, 1986, Pediatr Dermatol, V3, P271, DOI 10.1111/j.1525-1470.1986.tb00525.x
[47]   Spatial and temporal expression of perlecan in the early chick embryo [J].
Soulintzi, Nikolitsa ;
Zagris, Nikolas .
CELLS TISSUES ORGANS, 2007, 186 (04) :243-256
[48]   Localization of glycosaminoglycan substitution sites on domain V of mouse perlecan [J].
Tapanadechopone, P ;
Hassell, JR ;
Rigatti, B ;
Couchman, JR .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 265 (03) :680-690
[49]   Perlecan in late stages of osteoarthritis of the human knee joint [J].
Tesche, F ;
Miosge, N .
OSTEOARTHRITIS AND CARTILAGE, 2004, 12 (11) :852-862
[50]  
TIMPL R, 1979, J BIOL CHEM, V254, P9933